Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms:
VWK147
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | VWK147 is a second-generation HSP90 C-terminal domain (CTD) inhibitor. It acts on the CTD dimerization interface, preventing the dimerization of HSP90CTD, disrupting the binding of the co-chaperone protein PPID with HSP90CTD, and inhibiting dimerization-dependent functions of HSP90. VWK147 reduces the protein levels of HSP90 client proteins ULK1, RIPK1, and CDK4 without inducing a heat shock response. It induces cell death, including apoptosis (apoptosis), in both cisplatin-sensitive and resistant urothelial carcinoma cells. VWK147 causes LC3-II accumulation, inhibits autophagosome-lysosome fusion to block classical autophagy (autophagy), and triggers non-classical LC3 lipidation independent of the ULK1 and PIK3C3 complex. VWK147 is applicable to research on urothelial carcinoma. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.